Free shipping on all orders over $100 (US) and $300 (International) support@swisschems.is +1 (870) 533-5581

Product Usage: This product is intended for research purposes only.

All product information available on this website is for educational purposes only. Any form of bodily introduction into humans or animals is strictly prohibited by law. This product should only be handled by licensed and qualified professionals. It is not a drug, food, or cosmetic, and must not be misbranded, misused, or mislabeled as such.

Cartalax, 20mg

Quantity
Original price was: $70.00.Current price is: $61.95.
Same Trusted Formula. Fresh New Look.

During our packaging transition, you may receive products with either our previous or updated label. Rest assured, the formulation, purity and quality remain exactly same as standards.

Accepted Payment MethodsYour data is protected with 256-bit encryption.
Accepted payment methods
Shipping

Same-day shipping on USA orders placed before 2PM EST.

View Shipping Policy →
Returns

30-day hassle-free returns on unopened products.

View Returns Policy →
Lab Tested

Every batch is tested for purity, potency and quality.

View Lab Results →
Support

Have a question? Our team is here to help you.

Contact Us →

Cartalax is a cartilage-derived short peptide bioregulator from the Khavinson series with proposed tissue-specific regulatory activity in cartilaginous tissue. Research from the originating laboratory reports effects on chondrocyte signalling, collagen II synthesis, proteoglycan expression, and extracellular matrix regulation. Research applications include cartilage biology, chondrocyte function, ECM pathway investigation, and short peptide bioregulator mechanism studies. Independently third-party HPLC-tested; COA available per batch.

  • High Purity – 99% Purity Guaranteed
  • Independently Lab Tested
  • Research Grade Quality
  • For Laboratory Research Use Only

3D Molecular Structure

Drag to rotate · scroll to zoom
Loading 3D structure…
Chemical Formula C12H19N3O8
Synonyms T-31, AED, SCHEMBL5324601, Alanyl-glutamyl-aspartic acid
Molar Mass 333.29 g/mol
CAS Number 205640-90-0
PubChem CID 87815447
Total Compound Content 20 mg per vial
Shelf Life 36 months
Cartalax is a cartilage-derived short peptide bioregulator from the Khavinson series with proposed tissue-specific regulatory activity in cartilaginous tissue. Research from the originating laboratory reports effects on chondrocyte signalling, collagen II synthesis, proteoglycan expression, and extracellular matrix regulation. Research applications include cartilage biology, chondrocyte function, ECM pathway investigation, and short peptide bioregulator mechanism studies. Independently third-party HPLC-tested; COA available per batch.

Every batch is independently lab tested for identity, purity and potency. View our lab testing program →

What cartilage extracellular matrix markers have been examined in Cartalax research?

Research from the originating laboratory has focused on key cartilage extracellular matrix markers including collagen type II, aggrecan, and SOX9, which are central regulators of chondrocyte phenotype and cartilage matrix production. These markers are commonly used to evaluate cartilage signalling, extracellular matrix maintenance, and chondrocyte activity in experimental models.

How does Cartalax fit within the Khavinson bioregulator series?

Cartalax is the cartilage-focused member of the Khavinson peptide bioregulator series. Similar to other organ-specific bioregulators, it is proposed to influence tissue-specific regulatory pathways and is primarily investigated in studies involving cartilage biology, chondrocyte function, extracellular matrix regulation, and peptide-mediated gene expression mechanisms.

What experimental models are commonly used to investigate Cartalax?

Common models include primary chondrocyte cultures, cartilage-derived cell lines, three-dimensional cartilage culture systems, and rodent cartilage research models. Frequently measured endpoints include collagen II expression, aggrecan production, SOX9 signalling, extracellular matrix composition, glycosaminoglycan content, and chondrocyte proliferation markers.

Subscribe to receive our latest news

85% of users stay up-to-date with our newsletter